Roll back malaria
Malaria is one of the most deadly infectious diseases in the world. According to the World Health Organization, in 2010 malaria was responsible for 660,000 deaths worldwide, 90% of which occurred in Africa. Pregnant women and children under five years of age are the primary victims. In Africa, one child dies of malaria every minute (1).
Since 2001, Sanofi has pursued a strategy of partnership with all those who are active in the fight against malaria: scientists, health authorities, NGOs, etc.
Sanofi and the Drugs for Neglected initiative (DNDi) have developed an artemisinin combination therapy: ASAQ (Artesunate Amodiaquine) Winthrop®.
This antimalarial medication is sold to major international organizations, governments and NGOs using a differentiated pricing policy known as “no profit – no loss.”
Sanofi has set up a field monitoring program in collaboration with the National Malaria Control Programs of participating countries to collect information about the safety and efficacy of this antimalarial drug. The program is carried out in partnership with DNDi, Medicines for Malaria Venture (MMV), the WorldWide Antimalarial Resistance Network (WWARN) and many scientists.
Innovation continues today with the production of semisynthetic artemisinin. With the support of the Bill and Melinda Gates Foundation and in partnership with the Institute for OneWorld Health, the University of California at Berkeley, and Amyris Biotechnologies, Sanofi has developed an industrial manufacturing fermentation-based process to produce artemisinin. Sanofi received the Pierre Potier Science and Technology Prize in 2012 for this method, which makes it possible to ensure consistent yields, stabilize prices and shorten production times.
At the same time, one of our priorities is to discover new avenues of research to combat resistance to existing malaria treatments.
Our “Training the Trainers” program is designed to teach techniques for managing malaria to community health workers, who then become trainers themselves by passing along this knowledge. Other initiatives are organized to teach communities about ways to prevent malaria and to share this information with others.
Educating children is a key aspect of malaria prevention campaigns. Our Schoolchildren against Malaria program provides a panel of educational tools for teachers in Africa. Competitions are organized for schoolchildren – such as drawing contests and theatrical sketches – with awards going to the best projects that illustrate how to prevent malaria. With MOSKI-KIT, a set of games specially designed by Sanofi, children can learn basic information about malaria in an entertaining way.
1. WHO, WHO Global Malaria Programme, World Malaria Report 2012.
July 04, 2014
July 03, 2014